Are Microdosing Benefits Real? A New Study Says It May All Be In Your Mind
MIcrodosing with psychedelics is gaining in popularity but new research says the placebo effect worked just as well.
MIcrodosing with psychedelics is gaining in popularity but new research says the placebo effect worked just as well.
Defiance has launched the world’s second psychedelics-focused ETF as investing in psychedelic therapy and treatment accelerates.
Missouri residents with terminal or debilitating conditions may soon be able to access psychedelics under a new bill.
More than 30% of survey participants say they’re treating their mental health issues independently with the use of psychedelics.
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Mydecine (MYCO/MYCOF), Numinuss Wellness (NUMI), and Red Light Holland (TRIP).
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:35 – Imperial College Of London results of Study the effects of microdosing psychedelics and their impact on the psychedelic industry
5:45 – 15 Canadian healthcare professionals begin a historic psilocybin training program
6:55 – Chief of the Defense Force, Chris Barrie, is calling for psychedelic compounds like psilocybin and MDMA to be rescheduled
8:31 – A smartphone app called promises to induce a psychedelic like state (FUN)!
10:58 – MindMmed Stock News ( MMED/MMEDF/MMQ) and Company Updates
13:33 – Compass Pathways (CMPS) Stock News and Company Updates
15:22 – Atai Life Sciences Company News and IPO Speculation
16:42 – Numinus (NUMI) Stock News & 3 Company Updates
19:30 -Red Light Holland (TRIP) Stock News & Very Interesting Company Update
20:52 – Mydecine (MYCO/MYCOF) Stock News & Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Mushrooms have garnered plenty of attention for their psychedelic properties. Now the mushroom’s ts lesser-known cousin, psilocybin truffles is in the spotlight.
Whether trying psychedelics recreationally or clinically, you may wonder: just how do hallucinogens work? Here’s the guide to what to expect.
This week in psychedelic business news: two companies enter the Canadian Stock Exchange, AI comes to psychedelic treatment, and psilocybin comes to Brazil.
Biotech company Atai Life Sciences has earned a $2 billion valuation for its work in developing psychedelic treatments for mental health issues.
New York Times bestselling author Michael Pollan explores mescaline, opium, and caffeine in his forthcoming book “This Is Your Mind on Plants”.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.